title: Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil): experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer.
abstract: BACKGROUND
  We hypothesized that a response to pegylated liposomal doxorubicin (PLD, Caelyx/Doxil) followed by maintenance is beneficial and safe in recurrent ovarian cancer.
  
  
  METHODS
  Sixteen patients have received PLD for more than 1 year for recurrent ovarian (14) or fallopian tube (2) cancer. All had stable disease or better responses to PLD + carboplatin (5) or topotecan (9) doublets or to PLD alone (2). PLD maintenance therapy 30-40 mg/m(2) was given every 4-8 weeks. This analysis focuses on cardiac status, overall tolerance, and time to recurrence.
  
  
  RESULTS
  Termination of PLD was due to progression in all patients. Noteworthy was the lack of cumulative myelosuppression and, with one exception, clinical cardiac toxicity. This patient was hospitalized with cardiogenic shock and fever complicating grade 4 pancytopenia from topotecan ten months after discontinuation of PLD. Seven patients continue to receive PLD after a median of 1680 mg/m(2) (1180-2460 mg/m(2)). Four of these had documented relapses after 3-6 years on maintenance occurring in the setting of lengthening of the treatment interval. Maintenance PLD was reinstituted after 'reinduction' with a platinum.
  
  
  CONCLUSIONS
  PLD appears to be safe as long-term maintenance in ovarian cancer and may be important for a continued response.
authors.affiliation: Division of Medical Oncology, Department of Medicine, New York University School of Medicine, NYU Cancer Institute, New York, NY 10016, USA. andree02@med.nyu.edu
authors.forename: E
authors.initials: E
authors.lastname: Andreopoulou
authors.forename: D
authors.initials: D
authors.lastname: Gaiotti
authors.forename: E
authors.initials: E
authors.lastname: Kim
authors.forename: A
authors.initials: A
authors.lastname: Downey
authors.forename: D
authors.initials: D
authors.lastname: Mirchandani
authors.forename: A
authors.initials: A
authors.lastname: Hamilton
authors.forename: Allan
authors.initials: A
authors.lastname: Jacobs
authors.forename: John
authors.initials: J
authors.lastname: Curtin
authors.forename: F
authors.initials: F
authors.lastname: Muggia
mesh_terms: D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008081:Liposomes; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011092:Polyethylene Glycols
chemical_list: D000903:Antibiotics, Antineoplastic; D008081:Liposomes; D011092:Polyethylene Glycols; D004317:Doxorubicin